Short Interest in Protara Therapeutics, Inc. (NASDAQ:TARA) Rises By 510.9%

Protara Therapeutics, Inc. (NASDAQ:TARA) was the target of a significant growth in short interest in April. As of April 15th, there was short interest totalling 398,300 shares, a growth of 510.9% from the March 31st total of 65,200 shares. Approximately 4.4% of the shares of the company are short sold. Based on an average daily volume of 250,200 shares, the days-to-cover ratio is currently 1.6 days.

Analysts Set New Price Targets

Several research analysts have issued reports on TARA shares. HC Wainwright reiterated a “buy” rating and set a $23.00 price objective on shares of Protara Therapeutics in a research note on Monday, April 8th. Oppenheimer increased their price objective on Protara Therapeutics from $26.00 to $30.00 and gave the stock an “outperform” rating in a research note on Monday, April 22nd.

Protara Therapeutics Price Performance

Shares of NASDAQ:TARA traded down $0.12 during midday trading on Friday, reaching $2.93. The company’s stock had a trading volume of 255,029 shares, compared to its average volume of 623,671. Protara Therapeutics has a fifty-two week low of $1.04 and a fifty-two week high of $5.24. The company has a market capitalization of $33.43 million, a P/E ratio of -0.82 and a beta of 1.71. The business’s fifty day simple moving average is $3.72 and its 200-day simple moving average is $2.50.

Protara Therapeutics (NASDAQ:TARA) last announced its earnings results on Wednesday, March 13th. The company reported ($0.90) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.13. On average, analysts forecast that Protara Therapeutics will post -3.55 earnings per share for the current fiscal year.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.